본문 바로가기
KERD
논문KCI 등재

Nutritional Neuroscience as Mainstream of Psychiatry: The Evidence- Based Treatment Guidelines for Using Omega-3 Fatty Acids as a New Treatment for Psychiatric Disorders in Children and Adolescents

Kuan-Pin Su|Jane Pei-Chen Chang
대한정신약물학회 (Korean College of Neuropsychopharmacology)|2020.11|Clinical Psychopharmacology and Neuroscience|제18권 제4호|pp. 469-483|DOI 10.9758/cpn.2020.18.4.469

2

조회

0

다운로드

3

인용

0

참고문헌

키워드

Major depressive disorderAutism spectrum disorderInflammationAttention deficit disorder with hyperactivityAdolescent.Omega-3

초록

Omega-3 polyunsaturated fatty acids (or omega-3 PUFAs, n-3 PUFAs) are essential nutrients throughout the life span. Recent studies have shown the importance of n-3 PUFAs supplementation during prenatal and perinatal period as a potential protective factor of neurodevelopmental disorders. N-3 PUFAs have been reported to be lower in youth with attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD) and major depressive disorder (MDD). N-3 PUFAs supplementation has shown potential effects in the improvement of clinical symptoms in youth with ADHD, ASD, and MDD, especially those with high inflammation or a low baseline n-3 index. Moreover, it has been suggested that n-3 PUFAs had positive effects on lethargy and hyperactivity symptoms in ASD. For clinical application, the following dosage and duration are recommended in youth according to available randomized controlled trials and systemic literature review: (1) ADHD: a combination of eicosapentaenoic acid (EPA) ＋ docosahexaenoic acid (DHA) ≥ 750 mg/d, and a higher dose of EPA (1,200 mg/d) for those with inflammation or allergic diseases for duration of 16−24 weeks; (2) MDD: a combination of a EPA ＋ DHA of 1,000−2,000 mg/d, with EPA:DHA ratio of 2 to 1, for 12−16 weeks; (3) ASD: a combination of EPA ＋ DHA of 1,300−1,500 mg/d for 16−24 weeks as add-on therapy to target lethargy and hyperactivity symptoms. The current review also suggested that n-3 index and inflammation may be potential treatment response markers for youth, especially in ADHD and MDD, receiving n-3 PUFA.

Abstract

Omega-3 polyunsaturated fatty acids (or omega-3 PUFAs, n-3 PUFAs) are essential nutrients throughout the life span. Recent studies have shown the importance of n-3 PUFAs supplementation during prenatal and perinatal period as a potential protective factor of neurodevelopmental disorders. N-3 PUFAs have been reported to be lower in youth with attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD) and major depressive disorder (MDD). N-3 PUFAs supplementation has shown potential effects in the improvement of clinical symptoms in youth with ADHD, ASD, and MDD, especially those with high inflammation or a low baseline n-3 index. Moreover, it has been suggested that n-3 PUFAs had positive effects on lethargy and hyperactivity symptoms in ASD. For clinical application, the following dosage and duration are recommended in youth according to available randomized controlled trials and systemic literature review: (1) ADHD: a combination of eicosapentaenoic acid (EPA) ＋ docosahexaenoic acid (DHA) ≥ 750 mg/d, and a higher dose of EPA (1,200 mg/d) for those with inflammation or allergic diseases for duration of 16−24 weeks; (2) MDD: a combination of a EPA ＋ DHA of 1,000−2,000 mg/d, with EPA:DHA ratio of 2 to 1, for 12−16 weeks; (3) ASD: a combination of EPA ＋ DHA of 1,300−1,500 mg/d for 16−24 weeks as add-on therapy to target lethargy and hyperactivity symptoms. The current review also suggested that n-3 index and inflammation may be potential treatment response markers for youth, especially in ADHD and MDD, receiving n-3 PUFA.

참고문헌 (146)

  1. Das UN, "Essential fatty acids : biochemistry, physiology and pathology", Biotechnol J, 1, pp.420~439 (2006)
  2. Connor WE, "Importance of n-3 fatty acids in health and disease", Am J Clin Nutr, 71(1 Suppl), pp.171S~175S (2000)
  3. Torpy JM, "Eating fish : health benefits and risks", JAMA, 296, pp.1926~ (2006)
  4. Hibbeln JR, "Maternal seafood consumption in pregnancy and neurodevelopmental outcomes in childhood(ALSPAC study) : an observational cohort study", Lancet, 369, pp.578~585 (2007)
  5. Su KP, "Omega-3 fatty acids for major depressive disorder during pregnancy : results from a randomized, double-blind, placebo-controlled trial", J Clin Psychiatry, 69, pp.644~651 (2008)
  6. Su KP, "Omega-3 fatty acids in the prevention of interferon-alphainduced depression : results from a randomized, controlled trial", Biol Psychiatry, 76, pp.559~566 (2014)
  7. Chang JP, "Omega-3 polyunsaturated fatty acids in youths with attention deficit hyperactivity disorder : a systematic review and meta-analysis of clinical trials and biological studies", Neuropsychopharmacology, 43, pp.534~545 (2018)
  8. Chiu CC, "The effects of omega-3 fatty acids monotherapy in Alzheimer’s disease and mild cognitive impairment : a preliminary randomized double-blind placebo-controlled study", Prog Neuropsychopharmacol Biol Psychiatry, 32, pp.1538~1544 (2008)
  9. Chalon S, "Omega-3 fatty acids and monoamine neurotransmission", Prostaglandins Leukot Essent Fatty Acids, 75, pp.259~269 (2006)
  10. Su KP, "Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial", Eur Neuropsychopharmacol, 13, pp.267~271 (2003)
  11. Lin PY, "A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3fatty acids", J Clin Psychiatry, 68, pp.1056~1061 (2007)
  12. Chang JP, "High-dose eicosapentaenoic acid(EPA)improves attention and vigilance in children and adolescents with attention deficit hyperactivity disorder(ADHD)and low endogenous EPA levels", Transl Psychiatry, 9, pp.303~ (2019)
  13. Cheng YS, "Supplementation of omega 3 fatty acids may improve hyperactivity, lethargy, and stereotypy in children with autism spectrum disorders : a meta-analysis of randomized controlled trials", Neuropsychiatr Dis Treat, 13, pp.2531~2543 (2017)
  14. Chang JP, "More fish-happier mom, smarter child?", Brain Behav Immun, 73, pp.157~158 (2018)
  15. Labrousse VF, "Dietary omega-3 deficiency exacerbates inflammation and reveals spatial memory deficits in mice exposed to lipopolysaccharide during gestation", Brain Behav Immun, 73, pp.427~440 (2018)
  16. Lauritzen L, "DHA effects in brain development and function", Nutrients, 8, pp.6~ (2016)
  17. Agostoni C, "The first model of keeping energy balance and optimal psycho affective development : breastfed infants", J Affect Disord, 224, pp.10~15 (2017)
  18. Innis SM, "Omega-3 Fatty acids and neural development to 2years of age: do we know enough for dietary recommendations?", J Pediatr Gastroenterol Nutr, 48(Suppl 1), pp.S16~S24 (2009)
  19. Carver JD, "The relationship between age and the fatty acid composition of cerebral cortex and erythrocytes in human subjects", Brain Res Bull, 56, pp.79~85 (2001)
  20. Browning LM, "Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish", Am J Clin Nutr, 96, pp.748~758 (2012)
  21. Chang JP, "The lipid raft hypothesis : the relation among omega-3 fatty acids, depression and cardiovascular diseases", Taiwanese J Psychiatry, 24, pp.168~180 (2010)
  22. Chang JP, "Polyunsaturated fatty acids(PUFAs)levels in patients with cardiovascular diseases(CVDs)with and without depression", Brain Behav Immun, 44, pp.28~31 (2015)
  23. Su KP, "Biological mechanism of antidepressant effect of omega-3 fatty acids: how does fish oil act as a ‘mind-body interface’?", Neurosignals, 17, pp.144~152 (2009)
  24. Mazahery H, "Relationship between long chain n-3 polyunsaturated fatty acids and autism spectrum disorder : systematic review and meta-analysis of case-control and randomised controlled trials", Nutrients, 9, pp.155~ (2017)
  25. M SalLam, "Anti-inflammatory effect of Omega-3 polyunsaturated fatty acids in children with bronchial asthma; relation to nuclear factor-kappa B (NF-κB) and inflammatory cytokines il-12 and il-13", Egyptian Journal of Biochemistry and Molecular Biology, 28(2) (2010), African Journals Online (AJOL)[DOI]
  26. Zhang R, "Omega-3 polyunsaturated fatty acids inhibit the increase in cytokines and chemotactic factors induced in vitro by lymph fluid from an intestinal ischemia-reperfusion injury model", Nutrition, 31, pp.508~514 (2015)
  27. Farjadian S, "Effects of omega-3 fatty acids on serum levels of T-helper cytokines in children with asthma", Cytokine, 85, pp.61~66 (2016)
  28. Zhao Y, "Eicosapentaenoic acid prevents LPS-induced TNF-alpha expression by preventing NF-kappaB activation", J Am Coll Nutr, 23, pp.71~78 (2004)
  29. Farooqui AA, "Phospholipase A2-generated lipid mediators in the brain : the good, the bad, and the ugly", Neuroscientist, 12, pp.245~260 (2006)
  30. Rhee SH, "Principles and clinical implications of the brain-gut-enteric microbiota axis", Nat Rev Gastroenterol Hepatol, 6, pp.306~314 (2009)
  31. Ganesh BP, "Commensal Akkermansia muciniphila exacerbates gut inflammation in Salmonella Typhimurium-infected gnotobiotic mice", PLoS One, 8, pp.e74963~ (2013)
  32. Frank DN, "Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases", Proc Natl Acad Sci U S A, 104, pp.13780~13785 (2007)
  33. Watson H, "A randomised trial of the effect of omega-3 polyunsaturated fatty acid supplements on the human intestinal microbiota", Gut, 67, pp.1974~1983 (2018)
  34. Biederman J, "Attention-deficit hyperactivity disorder", Lancet, 366, pp.237~248 (2005)
  35. Biederman J, "Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders", Am J Psychiatry, 148, pp.564~577 (1991)
  36. Biederman J, "Evidence of familial association between attention deficit disorder and major affective disorders", Arch Gen Psychiatry, 48, pp.633~642 (1991)
  37. Wilens TE, "Alcohol, drugs, and attention-deficit", hyperactivity disorder : a model for the study of addictions in youth, 2006, pp.20, 580~588
  38. Volkow ND, "Clinical practice : adult attention deficit-hyperactivity disorder", N Engl J Med, 369, pp.1935~1944 (2013)
  39. Childress AC, "Attention-deficit", hyperactivity disorder with inadequate response to stimulants : approaches to management, 2014, pp.28, 121~129
  40. Chang JP, "Delay aversion, temporal processing, and n-3 fatty acids intake in children with attention-deficit", hyperactivity disorder(ADHD), 2016, pp.4, 1094~1103
  41. Stevens LJ, "Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder", Am J Clin Nutr, 62, pp.761~768 (1995)
  42. Stevens L, "EFA supplementation in children with inattention, hyperactivity, and other disruptive behaviors", Lipids, 38, pp.1007~1021 (2003)
  43. Colter AL, "Fatty acid status and behavioural symptoms of attention deficit hyperactivity disorder in adolescents : a case-control study", Nutr J, 7, pp.8~ (2008)
  44. Brookes KJ, "Association of fatty acid desaturase genes with attention-deficit", hyperactivity disorder, 2006, pp.60, 1053~1061
  45. Cooper RE, "Omega-3polyunsaturated fatty acid supplementation and cognition : a systematic review and meta-analysis", J Psychopharmacol, 29, pp.753~763 (2015)
  46. Gillies D, "Polyunsaturated fatty acids (PUFA) for attention deficit hyperactivity disorder (ADHD) in children and adolescents", Cochrane Database Syst Rev, 2012, pp.CD007986~ (2012)
  47. Hawkey E, "Omega-3 fatty acid and ADHD : blood level analysis and meta-analytic extension of supplementation trials", Clin Psychol Rev, 34, pp.496~505 (2014)
  48. Puri BK, "Which polyunsaturated fatty acids are active in children with attention-deficit hyperactivity disorder receiving PUFA supplementation? A fatty acid validated meta-regression analysis of randomized controlled trials", Prostaglandins Leukot Essent Fatty Acids, 90, pp.179~189 (2014)
  49. Sonuga-Barke EJ, "Nonpharmacological interventions for ADHD : systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments", Am J Psychiatry, 170, pp.275~289 (2013)
  50. Bloch MH, "Omega-3 fatty acid supplementation for the treatment of children with attention-deficit", hyperactivity disorder symptomatology : systematic review and meta-analysis, 2011, pp.50, 991~1000
  51. Manor I, "The effect of phosphatidylserine containing Omega3 fatty-acids on attention-deficit hyperactivity disorder symptoms in children : a double-blind placebo-controlled trial, followed by an open-label extension", Eur Psychiatry, 27, pp.335~342 (2012)
  52. Perera H, "Combined 3 and 6 supplementation in children with attention-deficit hyperactivity disorder(ADHD)refractory to methylphenidate treatment : a double-blind, placebo-controlled study", J Child Neurol, 27, pp.747~753 (2012)
  53. Richardson AJ, "A randomized double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties", Prog Neuropsychopharmacol Biol Psychiatry, 26, pp.233~239 (2002)
  54. Sinn N, "Cognitive effects of polyunsaturated fatty acids in children with attention deficit hyperactivity disorder symptoms : a randomised controlled trial", Prostaglandins Leukot Essent Fatty Acids, 78, pp.311~326 (2008)
  55. Vaisman N, "Correlation between changes in blood fatty acid composition and visual sustained attention performance in children with inattention : effect of dietary n-3fatty acids containing phospholipids", Am J Clin Nutr, 87, pp.1170~1180 (2008)
  56. Voigt RG, "A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit", hyperactivity disorder, 2001, pp.139, 189~196
  57. Widenhorn-Müller K, "Effect of supplementation with long-chain ω-3 polyunsaturated fatty acids on behavior and cognition in children with attention deficit", hyperactivity disorder (ADHD): a randomized placebo-controlled intervention trial, 2014, pp.91, 49~60
  58. American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: DSM-5" (2013), American Psychiatric Association
  59. Marchezan J, "Immunological dysfunction in autism spectrum disorder : a potential target for therapy", Neuroimmunomodulation, 25, pp.300~319 (2018)
  60. Rossignol DA, "Evidence linking oxidative stress, mitochondrial dysfunction, and inflammation in the brain of individuals with autism", Front Physiol, 5, pp.150~ (2014)
  61. Napoli E, "Deficits in bioenergetics and impaired immune response in granulocytes from children with autism", Pediatrics, 133, pp.e1405~e1410 (2014)
  62. El-Ansary A, "Lipid mediators in plasma of autism spectrum disorders", Lipids Health Dis, 11, pp.160~ (2012)
  63. Adams JB, "The severity of autism is associated with toxic metal body burden and red blood cell glutathione levels", J Toxicol, 2009, pp.532640~ (2009)
  64. Rojas DC, "Regional gray matter volumetric changes in autism associated with social and repetitive behavior symptoms", BMC Psychiatry, 6, pp.56~ (2006)
  65. Pryweller JR, "White matter correlates of sensory processing in autism spectrum disorders", Neuroimage Clin, 6, pp.379~387 (2014)
  66. Bryn V, "Brain derived neurotrophic factor(BDNF)and autism spectrum disorders(ASD)in childhood", Eur J Paediatr Neurol, 19, pp.411~414 (2015)
  67. Cao D, "Effects of docosahexaenoic acid on the survival and neurite outgrowth of rat cortical neurons in primary cultures", J Nutr Biochem, 16, pp.538~546 (2005)
  68. Robson LG, "Omega-3polyunsaturated fatty acids increase the neurite outgrowth of rat sensory neurones throughout development and in aged animals", Neurobiol Aging, 31, pp.678~687 (2010)
  69. Calderon F, "Docosahexaenoic acid promotes neurite growth in hippocampal neurons", J Neurochem, 90, pp.979~988 (2004)
  70. Wu A, "Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats", J Neurotrauma, 21, pp.1457~1467 (2004)
  71. Brigandi SA, "Autistic children exhibit decreased levels of essential Fatty acids in red blood cells", Int J Mol Sci, 16, pp.10061~10076 (2015)
  72. Abdelmagid SA, "Ethnicity, sex, FADS genetic variation, and hormonal contraceptive use influence delta-5- and delta-6-desaturase indices and plasma docosahexaenoic acid concentration in young Canadian adults: a cross-sectional study", Nutr Metab (Lond), 12, pp.14~ (2015)
  73. Chouinard-Watkins R, "Fatty acid metabolism in carriers of apolipoprotein E epsilon 4 allele: is it contributing to higher risk of cognitive decline and coronary heart disease?", Nutrients, 6, pp.4452~4471 (2014)
  74. Shimamoto C, "Functional characterization of FABP3, 5 and 7 gene variants identified in schizophrenia and autism spectrum disorder and mouse behavioral studies", Hum Mol Genet, 23, pp.6495~6511 (2014)
  75. Al-Farsi YM, "Impact of nutrition on serum levels of docosahexaenoic acid among Omani children with autism", Nutrition, 29, pp.1142~1146 (2013)
  76. Ghezzo A, "Oxidative stress and erythrocyte membrane alterations in children with autism : correlation with clinical features", PLoS One, 8, pp.e66418~ (2013)
  77. Meiri G, "Omega 3 fatty acid treatment in autism", J Child Adolesc Psychopharmacol, 19, pp.449~451 (2009)
  78. Ooi YP, "Omega-3 fatty acids in the management of autism spectrum disorders : findings from an open-label pilot study in Singapore", Eur J Clin Nutr, 69, pp.969~971 (2015)
  79. Amminger GP, "Omega-3 fatty acids supplementation in children with autism : a double-blind randomized, placebo-controlled pilot study", Biol Psychiatry, 61, pp.551~553 (2007)
  80. Mankad D, "A randomized, placebo controlled trial of omega-3 fatty acids in the treatment of young children with autism", Mol Autism, 6, pp.18~ (2015)
  81. Katan MB, "Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, and adipose tissue : an 18-month controlled study", J Lipid Res, 38, pp.2012~2022 (1997)
  82. Stonehouse W, "Does consumption of LC omega-3 PUFA enhance cognitive performance in healthy school-aged children and throughout adulthood? Evidence from clinical trials", Nutrients, 6, pp.2730~2758 (2014)
  83. Raine A, "Reduction in behavior problems with omega-3 supplementation in children aged 8-16 years : a randomized, double-blind, placebo-controlled, stratified, parallel-group trial", J Child Psychol Psychiatry, 56, pp.509~520 (2015)
  84. Horvath A, "ω-3 fatty acid supplementation does not affect autism spectrum disorder in children:a systematic review and meta-analysis", J Nutr, 147, pp.367~376 (2017)
  85. March JS, "The Treatment for Adolescents with Depression Study(TADS) : long-term effectiveness and safety outcomes", Arch Gen Psychiatry, 64, pp.1132~1143 (2007)
  86. Chang JP, "Polyunsaturated fatty acids and inflammatory markers in major depressive episodes during pregnancy", Prog Neuropsychopharmacol Biol Psychiatry, 80(Pt C), pp.273~278 (2018)
  87. Hibbeln JR, "Healthy intakes of n-3 and n-6 fatty acids : estimations considering worldwide diversity", Am J Clin Nutr, 83(6Suppl), pp.1483S~1493S (2006)
  88. Chang JP, "Omega-3 polyunsaturated fatty acids in cardiovascular diseases comorbid major depressive disorder-results from a randomized controlled trial", Brain Behav Immun, 85, pp.14~20 (2020)
  89. Peet M, "A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs", Arch Gen Psychiatry, 59, pp.913~919 (2002)
  90. Stoll AL, "Omega 3 fatty acids in bipolar disorder : a preliminary double-blind, placebo-controlled trial", Arch Gen Psychiatry, 56, pp.407~412 (1999)
  91. Chiu CC, "Omega-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder", J Clin Psychiatry, 66, pp.1613~1614 (2005)
  92. Su KP, "Are omega3 fatty acids beneficial in depression but not mania?", Arch Gen Psychiatry, 57, pp.716~717 (2000)
  93. Guida F, "Antibiotic-induced microbiota perturbation causes gut endocannabinoidome changes, hippocampal neuroglial reorganization and depression in mice", Brain Behav Immun, 67, pp.230~245 (2018)
  94. Kelly JR, "Transferring the blues : depression-associated gut microbiota induces neurobehavioural changes in the rat", J Psychiatr Res, 82, pp.109~118 (2016)
  95. Zheng P, "Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host’s metabolism", Mol Psychiatry, 21, pp.786~796 (2016)
  96. van de Wouw M, "Short-chain fatty acids : microbial metabolites that alleviate stress-induced brain-gut axis alterations", J Physiol, 596, pp.4923~4944 (2018)
  97. Jiang H, "Altered fecal microbiota composition in patients with major depressive disorder", Brain Behav Immun, 48, pp.186~194 (2015)
  98. Tedelind S, "Anti-inflammatory properties of the short-chain fatty acids acetate and propionate : a study with relevance to inflammatory bowel disease", World J Gastroenterol, 13, pp.2826~2832 (2007)
  99. Bourassa MW, "Butyrate, neuroepigenetics and the gut microbiome : can a high fiber diet improve brain health", Neurosci Lett, 625, pp.56~63 (2016)
  100. Trompette A, "Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis", Nat Med, 20, pp.159~166 (2014)
  101. Sgoifo A, "Autonomic dysfunction and heart rate variability in depression", Stress, 18, pp.343~352 (2015)
  102. Paniccia M, "Heart rate variability in healthy non-concussed youth athletes : exploring the effect of age, sex, and concussion-like symptoms", Front Neurol, 8, pp.753~ (2018)
  103. Vloet TD, "Mean heart rate and parameters of heart rate variability in depressive children and the effects of antidepressant medication", Z Kinder Jugendpsychiatr Psychother, 47, pp.253~260 (2019)
  104. Hibbeln JR, "Omega-3 fatty acid deficiencies in neurodevelopment, aggression and autonomic dysregulation : opportunities for intervention", Int Rev Psychiatry, 18, pp.107~118 (2006)
  105. Christensen JH, "Omega-3 polyunsaturated fatty acids and heart rate variability", Front Physiol, 2, pp.84~ (2011)
  106. Lauritzen L, "The effect of fish oil supplementation on heart rate in healthy Danish infants", Pediatr Res, 64, pp.610~614 (2008)
  107. Pivik RT, "Early infant diet and the omega 3 fatty acid DHA : effects on resting cardiovascular activity and behavioral development during the first half-year of life", Dev Neuropsychol, 34, pp.139~158 (2009)
  108. Chang JP, "BanI polymorphism of cytosolic phospholipase A2 gene and somatic symptoms in medication-free acute depressed patients", Prostaglandins Leukot Essent Fatty Acids, 136, pp.111~115 (2018)
  109. Su KP, "Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels", Biol Psychiatry, 67, pp.550~557 (2010)
  110. Guu TW, "International Society for Nutritional Psychiatry Research practice guidelines for omega-3 fatty acids in the treatment of major depressive disorder", Psychother Psychosom, 88, pp.263~273 (2019)
  111. Nishi D, "The efficacy of omega-3 fatty acids for depressive symptoms among pregnant women in Japan and Taiwan : a randomized, double-blind, placebo-controlled trial(SYNCHRO; NCT01948596)", Psychother Psychosom, 88, pp.122~124 (2019)
  112. Nishi D, "Plasma estradiol levels and antidepressant effects of omega-3 fatty acids in pregnant women", Brain Behav Immun, 85, pp.29~34 (2020)
  113. Nishi D, "Omega-3 fatty acid supplementation for expectant mothers with depressive symptoms in Japan and Taiwan : An open-label trial", Psychiatry Clin Neurosci, 70, pp.253~254 (2016)
  114. McNamara RK, "Detection and treatment of long-chain omega-3 fatty acid deficiency in adolescents with SSRI-resistant major depressive disorder", PharmaNutrition, 2, pp.38~46 (2014)
  115. Gabbay V, "A double-blind placebo-controlled trial of omega-3 fatty acids as a monotherapy for adolescent depression", J Clin Psychiatry, 79, pp.17~ (2018)
  116. Nemets H, "Omega-3 treatment of childhood depression : a controlled, double-blind pilot study", Am J Psychiatry, 163, pp.1098~1100 (2006)
  117. Trebatická J, "Emulsified omega-3 fatty-acids modulate the symptoms of depressive disorder in children and adolescents : a pilot study", Child Adolesc Psychiatry Ment Health, 11, pp.30~ (2017)
  118. Harris WS, "Expert opinion: omega-3 fatty acids and bleeding-cause for concern?", Am J Cardiol, 99, pp.44C~46C (2007)
  119. Matsuo N, "Studies on the toxicity of fish oil. V. Toxicity of oxidized commercial cod-liver oil", Tokushima J Exp Med, 8, pp.96~100 (1961)
  120. Palozza P, "N-3 fatty acids induce oxidative modifications in human erythrocytes depending on dose and duration of dietary supplementation", Am J Clin Nutr, 64, pp.297~304 (1996)
  121. Grundt H, "Increased lipid peroxidation during long-term intervention with high doses of n-3 fatty acids(PUFAs)following an acute myocardial infarction", Eur J Clin Nutr, 57, pp.793~800 (2003)
  122. Halvorsen B, "Effects of partially hydrogenated fish oil, partially hydrogenated soybean oil and butter on the susceptibility of low density lipoprotein to oxidative modification in men", Eur J Clin Nutr, 50, pp.364~370 (1996)
  123. Calviello G, "Low-dose eicosapentaenoic or docosahexaenoic acid administration modifies fatty acid composition and does not affect susceptibility to oxidative stress in rat erythrocytes and tissues", Lipids, 32, pp.1075~1083 (1997)
  124. Turley E, "Fish oil supplementation with and without added vitamin E differentially modulates plasma antioxidant concentrations in healthy women", Lipids, 33, pp.1163~1167 (1998)
  125. Linseisen J, "Antioxidant status of surgical patients receiving TPN with an omega-3-fatty acid-containing lipid emulsion supplemented with alpha-tocopherol", Clin Nutr, 19, pp.177~184 (2000)
  126. Higdon JV, "Supplementation of postmenopausal women with fish oil does not increase overall oxidation of LDL ex vivo compared to dietary oils rich in oleate and linoleate", J Lipid Res, 42, pp.407~418 (2001)
  127. Higgins S, "Susceptibility of LDL to oxidative modification in healthy volunteers supplemented with low doses of n-3 polyunsaturated fatty acids", Br J Nutr, 85, pp.23~31 (2001)
  128. Rhodes LE, "Effect of eicosapentaenoic acid, an omega-3 polyunsaturated fatty acid, on UVRrelated cancer risk in humans. An assessment of early genotoxic markers", Carcinogenesis, 24, pp.919~925 (2003)
  129. Wheaton DH, "Biological safety assessment of docosahexaenoic acid supplementation in a randomized clinical trial for X-linked retinitis pigmentosa", Arch Ophthalmol, 121, pp.1269~1278 (2003)
  130. Tholstrup T, "A solid dietary fat containing fish oil redistributes lipoprotein subclasses without increasing oxidative stress in men", J Nutr, 134, pp.1051~1057 (2004)
  131. Mohan IK, "Oxidant stress, anti-oxidants and essential fatty acids in systemic lupus erythematosus", Prostaglandins Leukot Essent Fatty Acids, 56, pp.193~198 (1997)
  132. Wander RC, "Influence of long-chain polyunsaturated fatty acids on oxidation of low density lipoprotein", Prostaglandins Leukot Essent Fatty Acids, 59, pp.143~151 (1998)
  133. Véricel E, "The influence of low intake of n-3 fatty acids on platelets in elderly people", Atherosclerosis, 147, pp.187~192 (1999)
  134. Ramírez-Tortosa MC, "Effect of extra-virgin olive oil and fish-oil supplementation on plasma lipids and susceptibility of lowdensity lipoprotein to oxidative alteration in free-living Spanish male patients with peripheral vascular disease", Clin Nutr, 18, pp.167~174 (1999)
  135. Mori TA, "Effect of omega 3 fatty acids on oxidative stress in humans : GC-MS measurement of urinary F2-isoprostane excretion", Redox Rep, 5, pp.45~46 (2000)
  136. Yavin E, "Docosahexaenoic acid accumulation in the prenatal brain : prooxidant and antioxidant features", J Mol Neurosci, 16, pp.229~235 (2001)
  137. Jain S, "Effects of low-dose omega-3 fatty acid substitution in type-2 diabetes mellitus with special reference to oxidative stress--a prospective preliminary study", J Assoc Physicians India, 50, pp.1028~1033 (2002)
  138. Mori TA, "Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects", Free Radic Biol Med, 35, pp.772~781 (2003)
  139. Barbosa DS, "Decreased oxidative stress in patients with ulcerative colitis supplemented with fish oil omega-3 fatty acids", Nutrition, 19, pp.837~842 (2003)
  140. Abel S, "Dietary modulation of fatty acid profiles and oxidative status of rat hepatocyte nodules : effect of different n-6", n-3 fatty acid ratios, 2004, pp.39, 963~976
  141. Parinyasiri U, "Effect of fish oil on oxidative stress, lipid profile and renal function in IgA nephropathy", J Med Assoc Thai, 87, pp.143~149 (2004)
  142. Chang CH, "Safety and tolerability of prescription omega-3 fatty acids : a systematic review and meta-analysis of randomized controlled trials", Prostaglandins Leukot Essent Fatty Acids, 129, pp.1~12 (2018)
  143. Siscovick DS, "Omega-3 polyunsaturated fatty acid(fish oil)supplementation and the prevention of clinical cardiovascular disease : a science advisory from the American Heart Association", Circulation, 135, pp.e867~e884 (2017)
  144. Bradberry JC, "Overview of omega-3 fatty acid therapies", P T, 38, pp.681~691 (2013)
  145. Rapaport MH, "Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder : a proof-of-concept study", Mol Psychiatry, 21, pp.71~79 (2016)
  146. Lin PY, "Are omega-3 fatty acids antidepressants or just mood-improving agents? The effect depends upon diagnosis, supplement preparation, and severity of depression", Mol Psychiatry, 17, pp.1161~1163 (2012)

관련 논문AI추천

Omega-3 Polyunsaturated Fatty Acids in Prevention of Mood and Anxiety Disorders배치운, Kuan-Pin Su, Yutaka Matsuoka대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2015 · 제13권 제2호Effect of Omega-3 and Korean Red Ginseng on Children with Attention Deficit Hyperactivity Disorder: An Open-Label Pilot Study김성주, 김지훈, 이지원, Areum Lee, Soyoung Irene Lee, Woo Dong Cho, Yun Mi Shin대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2020 · 제18권 제1호Correlation between Vitamin B12 and Mental Health in Children and Adolescents: A Systematic Review and Meta-analysisCaihong Xie, Hua Hu, Jiani Wang, Kaiqi Gu, Lijun Cha, Li Zhou, Qin Yang, Xia Chen, Xiaosong Song, Yongjun Tan, Youlin Wu, Yuhan Wang대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2023 · 제21권 제4호Role of n-3 long-chain polyunsaturated fatty acids in human nutrition and health: review of recent studies and recommendationsPeter Van Dael한국영양학회 · Nutrition Research and Practice2021 · 제15권 제2호주의력 결핍 성향이 있는 비행청소년의 충동성 감소를 위한 인지행동 치료 시 고도불포화지방산의 병용효과강영숙, 김복희, 이수정, 이창선한국심리학회 · 한국심리학회지:일반2008 · 제27권 제3호Vitamin D Supplementation is Beneficial for Children with Autism Spectrum Disorder: A Meta-analysisAi Chen, Dan Wang, Lifang Zhou, Liyao Song, Qing Jiang, Xiaomei Luo, Zhi Chen대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2020 · 제18권 제2호

이 간행물의 다른 논문 (17건)

How to Utilize Clinical and Genetic Information for Personalized Treatment of Major Depressive Disorder: Step by Step Strategic ApproachAlessandro Serretti, Chiara Fabbripp. 484-492Recent Advances in the Pharmacology of Tardive DyskinesiaStanley N. Caroffpp. 493-506Kynurenine Pathway of Tryptophan Metabolism in Neuropsychiatric Disorders: Pathophysiologic and Therapeutic ConsiderationsAther Muneerpp. 507-526Effects of Non-invasive Neurostimulation on Autism Spectrum Disorder: A Systematic ReviewHadi Zarafshan, Ali Khaleghi, Mohammad Reza Mohammadi, Safa Rafieivandpp. 527-552Associations among High Risk for Sleep-disordered Breathing, Related Risk Factors, and Attention Deficit/Hyperactivity Symptoms in Elementary School ChildrenDohyun Kim, Myung-Ho Lim, Hyunjoo Joo, Seung Jin Yoo, Mina Ha, Ki-Chung Paik, Hojang Kwon, Eun Jung Kim, Jee Hyun Kim, 김경민pp. 553-561
원문 보기